MovDisordV3, Main, Exploration, bibRecord, 004932

Tolerability of paroxetine in Parkinson's disease: A prospective study

Identifieur interne : 004932 ( Main/Exploration ); précédent : 004931; suivant : 004933

Tolerability of paroxetine in Parkinson's disease: A prospective study

Auteurs : Silvana Tesei [Italie] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Anna Zecchinelli [Italie] ; Claudio B. Mariani [Italie] ; Gianni Pezzoli [Italie]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-09.

RBID : ISTEX:866417BCF8933A1A097A3C9EC708B2D1E9EFB85F

Descripteurs français

Pascal (Inist)
- Antidépresseur, Chimiothérapie, Complication, Etat dépressif, Inhibiteur recapture, Parkinson maladie, Paroxétine, Personne âgée, Pipéridine dérivé, Sérotonine, Toxicité, Traitement.
Wicri :
- topic : Personne âgée.

English descriptors

KwdEn :
- Aged, Antidepressant agent, Antiparkinson Agents (therapeutic use), Chemotherapy, Clinical Protocols, Complication, Depression, Depression (drug therapy), Depression (etiology), Dose-Response Relationship, Drug, Drug Therapy, Combination, Elderly, Female, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson disease, Parkinson's, Paroxetine, Paroxetine (administration & dosage), Paroxetine (adverse effects), Paroxetine (therapeutic use), Piperidine derivatives, Prospective Studies, Reuptake inhibitor, SSRI, Safety, Serotonin, Serotonin Uptake Inhibitors (administration & dosage), Serotonin Uptake Inhibitors (adverse effects), Serotonin Uptake Inhibitors (therapeutic use), Tolerability, Toxicity, Treatment, Treatment Outcome, disease.
MESH :
- chemical , administration & dosage : Paroxetine, Serotonin Uptake Inhibitors.
- chemical , adverse effects : Paroxetine, Serotonin Uptake Inhibitors.
- chemical , therapeutic use : Antiparkinson Agents, Paroxetine, Serotonin Uptake Inhibitors.
- complications : Parkinson Disease.
- drug therapy : Depression, Parkinson Disease.
- etiology : Depression.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Aged, Clinical Protocols, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome.

Abstract

Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.

Url:

https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/pdf

DOI: 10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title>
<author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name>
</author>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
</author>
<author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name>
</author>
<author><name sortKey="Mariani, Claudio B" sort="Mariani, Claudio B" uniqKey="Mariani C" first="Claudio B." last="Mariani">Claudio B. Mariani</name>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</idno>
<idno type="url">https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003036</idno>
<idno type="wicri:Area/Istex/Curation">003036</idno>
<idno type="wicri:Area/Istex/Checkpoint">003132</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Tesei S:tolerability:of:paroxetine</idno>
<idno type="wicri:Area/Main/Merge">007229</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0480422</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B53</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000168</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002A91</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Tesei S:tolerability:of:paroxetine</idno>
<idno type="wicri:Area/Main/Merge">007483</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11009210</idno>
<idno type="wicri:Area/PubMed/Corpus">003E95</idno>
<idno type="wicri:Area/PubMed/Curation">003E95</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E46</idno>
<idno type="wicri:Area/Ncbi/Merge">000356</idno>
<idno type="wicri:Area/Ncbi/Curation">000356</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000356</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Tesei S:tolerability:of:paroxetine</idno>
<idno type="wicri:Area/Main/Merge">006F89</idno>
<idno type="wicri:Area/Main/Curation">004932</idno>
<idno type="wicri:Area/Main/Exploration">004932</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title>
<author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mariani, Claudio B" sort="Mariani, Claudio B" uniqKey="Mariani C" first="Claudio B." last="Mariani">Claudio B. Mariani</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<affiliation wicri:level="3"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-09">2000-09</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="986">986</biblScope>
<biblScope unit="page" to="989">989</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</idno>
<idno type="DOI">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</idno>
<idno type="ArticleID">MDS1034</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antidepressant agent</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Clinical Protocols</term>
<term>Complication</term>
<term>Depression</term>
<term>Depression (drug therapy)</term>
<term>Depression (etiology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination</term>
<term>Elderly</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Parkinson's</term>
<term>Paroxetine</term>
<term>Paroxetine (administration & dosage)</term>
<term>Paroxetine (adverse effects)</term>
<term>Paroxetine (therapeutic use)</term>
<term>Piperidine derivatives</term>
<term>Prospective Studies</term>
<term>Reuptake inhibitor</term>
<term>SSRI</term>
<term>Safety</term>
<term>Serotonin</term>
<term>Serotonin Uptake Inhibitors (administration & dosage)</term>
<term>Serotonin Uptake Inhibitors (adverse effects)</term>
<term>Serotonin Uptake Inhibitors (therapeutic use)</term>
<term>Tolerability</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Paroxetine</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Paroxetine</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Paroxetine</term>
<term>Serotonin Uptake Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Clinical Protocols</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antidépresseur</term>
<term>Chimiothérapie</term>
<term>Complication</term>
<term>Etat dépressif</term>
<term>Inhibiteur recapture</term>
<term>Parkinson maladie</term>
<term>Paroxétine</term>
<term>Personne âgée</term>
<term>Pipéridine dérivé</term>
<term>Sérotonine</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
<region><li>Lombardie</li>
</region>
<settlement><li>Milan</li>
</settlement>
</list>
<tree><country name="Italie"><region name="Lombardie"><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name>
</region>
<name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name>
<name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name>
<name sortKey="Mariani, Claudio B" sort="Mariani, Claudio B" uniqKey="Mariani C" first="Claudio B." last="Mariani">Claudio B. Mariani</name>
<name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name>
<name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004932 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004932 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:866417BCF8933A1A097A3C9EC708B2D1E9EFB85F
   |texte=   Tolerability of paroxetine in Parkinson's disease: A prospective study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Tolerability of paroxetine in Parkinson's disease: A prospective study

Tolerability of paroxetine in Parkinson's disease: A prospective study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.